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Abstract
Since airway hyperresponsiveness (AHR) and allergic inflammatory changes are regarded as the
primary manifestations of asthma, the main goals of asthma treatment are to decrease inflammation
and maximize bronchodilation. These goals can be achieved with aerosol therapy. Intravenous
administration of the anesthetic, ketamine, has been shown to trigger bronchial smooth muscle
relaxation. Furthermore, increasing evidence suggests that the anti-inflammatory properties of
ketamine may protect against lung injury. However, ketamine inhalation might yield the same or
better results at higher airway and lower ketamine plasma concentrations for the treatment of
asthma. Here, we studied the effect of ketamine inhalation on bronchial hyperresponsiveness and
airway inflammation in a Brown-Norway rat model of ovalbumin(OVA)-induced allergic asthma.
Animals were actively sensitized by subcutaneous injection of OVA and challenged by repeated
intermittent (thrice weekly) exposure to aerosolized OVA for two weeks. Before challenge, the
sensitizened rats received inhalation of aerosol of phosphate-buffered saline (PBS) or aerosol of
ketamine or injection of ketamine respectivity. Airway reactivity to acetylcholine (Ach) was
measured in vivo, and various inflammatory markers, including Th2 cytokines in bronchoalveolar
lavage fluid (BALF), as well as induciable nitric oxide synthase (iNOS) and nitric oxide (NO) in lungs
were examined. Our results revealed that delivery of aerosolized ketamine using an ultrasonic
nebulizer markedly suppressed allergen-mediated airway hyperreactivity, airway inflammation and
airway inflammatory cell infiltration into the BALF, and significantly decreased the levels of
interleukin-4 (IL-4) in the BALF and expression of iNOS and the concentration of NO in the
inflamed airways from OVA-treated rats. These findings collectively indicate that nebulized
ketamine attenuated many of the central components of inflammatory changes and AHR in OVA-
provoked experimental asthma, potentially providing a new therapeutic approach against asthma.
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Background
Asthma is characterized by acute and chronic airway
inflammation, in which the severity of airway hyperreac-
tivity (AHR) is correlated with the degree of inflammation
[1]. Based on our growing understanding of asthma
pathogenesis, the various treatment strategies are prima-
rily focused on decreasing inflammation and maximizing
bronchodilation. Inhalotherapy represents the main
method currently used for treating respiratory disorders,
because it has the benefit of allowing drugs to be delivered
directly to the large surfaces of the tracheobronchial tree
and alveoli [2]. Inhaled drugs play an important role in
asthma management, as many of the beta-adrenergic and
anti-cholinergic bronchodilators, corticosteroids, and
nonsteroidal anti-inflammatory agents currently used in
the treatment of acute asthma are administered as inhaled
gases or aerosols [3]. However, although steroids and
beta-agonists form the mainstay of asthma therapy, the
symptoms in some asthmatics are poorly controlled with
these drugs, and their therapeutic benefits may be out-
weighed to some degree by their undesirable side effects
[4]. Thus, researchers continue to seek and evaluate addi-
tional drugs capable of modulating inflammatory
responses and AHR in the treatment of asthma.
The intravenous anesthetic, ketamine, was first used in
humans in 1965 and is still applied in a variety of clinical
settings today. Ketamine has many pharmacological prop-
erties, including analgesic, anesthetic and sympathomi-
metic effects [5]. Owing to its ability to induce relaxation
of bronchial smooth muscle, ketamine is recommended
as an optimizing anesthetic for asthmatic patients, and
has been clinically used to treat bronchospasms, asthma
exacerbation and status asthmaticus [6-8]. In recent years,
studies have shown that ketamine plays a protective role
against lung injury, via its anti-inflammatory properties.
For example, under ketamine anesthesia, neurogenic pul-
monary edema is less pronounced in a rat model of spinal
cord injury [9], and the mortality of severely burnt rats is
reduced [10]. In addition, ketamine has been shown to
attenuate symptoms of endotoxemia in a lipopolysaccha-
ride (LPS)-induced rat model of of sepsis, by reducing NF-
kappa B activity and TNF-alpha production [11], and
decreasing the expression of inducible nitric oxide syn-
thase (iNOS) [12], which has been implicated in endo-
toxin-induced tissue injury. Taken together, these results
suggest that ketamine has anti-inflammatory and anti-
hyperresponsiveness effects, and could prove useful for
the treatment of asthma. However, the use of ketamine in
asthma patients has been limited by the risk of adverse
systemic effects following administration by the conven-
tional route of intravenous injection [13]. Studies into the
nasal, oral, and rectal administration of ketamine have
suggest that local use of this drug is both effective and
plausible [14-16]. However, no previous work has investi-
gated the possible use of ketamine inhalation for treat-
ment in asthma.
The aim of this investigation was to evaluate whether ket-
amine treatment by the inhaled route could prove effi-
cient and safe for the treatment of asthma. We examined
the effect of nebulized ketamine inhalation on allergen-
induced AHR and inflammatory changes in OVA-sensi-
tized Brown-Norway rats, a model in which chronic OVA
challenge is used to stimulate airway inflammation and
AHR [17]. We tested airway reactivity to Ach, lung pathol-
ogy, levels of Th2 cytokines in the BALF, and NOS expres-
sion and NO production in lung tissues. We compared
these effects to those seen in OVA-treated rats receiving
systemic administration of ketamine via the intraperito-
neal (i.p.) injection, and lastly tested the effects of differ-
ent concentrations of nebulized ketamine on lung tissues
and plasma levels in normal, non-allergic rats.
Methods
Sensitization and challenge protocol
Specific pathogen-free, inbred male Brown-Norway rats
(strain BN/CrlBR), 7–11 weeks old and weighing between
130–170 g, were purchased from Beijing Vitalriver Labo-
ratory Animal Co. (Beijing, China) and maintained in SPF
rooms in an animal facility of the Nanjing Medical Uni-
versity (Jiangsu Province, China, SYXK 2002-0013). All
animal care protocols and experimental procedures were
performed according to institutional guidelines and con-
formed to the requirements of the state authority for ani-
mal research conduct.
Rats were randomly assigned to ten experimental groups
(n = 6–8 rats), and the sensitization and challenge proto-
cols were performed according to Elwood et al. [17] and
Vanacker et al. [18], with some modifications, as
described below.
On days (d) 0 and 7, rats were activily sensitized by sub-
cutaneous injection of 1 mg OVA(Grade V, Sigma-aldrich,
Inc. Missouri, USA) and 100 mg aluminum hydroxide
[Al(OH)3; Jingshan Chemicals Co., Shanghai, China] in 1
ml PBS. Simultaneously, each rat received an intraperito-
neal injection of 1 ml Bordetella pertussis (National Insti-
tute for the Control of Pharmaceutical and Biological
Products, Beijing, China) containing 6 × 109 heat-killed
bacilli as an adjuvant.
PBS control group (sensitized/PBS-exposed rats, n = 8)
From d 13 to d 26, the sensitized rats were exposed to aer-
osolized PBS for 30 minutes each day.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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OVA control group (sensitized/PBS-exposed/OVA-challenged rats, n = 
8)
Sensitized rats were exposed to aerosolized PBS for 30
min per day on odd days from d 13 to d 25, and chal-
lenged with 10 mg/ml OVA (1 g OVA in 100 ml sterile PBS
in the nebulizer) for 30 min per day on even days from d
14 to d 26.
12.5 mg/ml inhaled test group (sensitized/12.5 mg/ml ketamine-
exposed/OVA-challenged rats, n = 8)
Sensitized rats were exposed to 12.5 mg/ml ketamine [100
mg/2 ml Ketamine Hydrochloride Injection (H32025255;
Jiangsu HengRui Medicine Co., China) diluted to 12.5
mg/ml with 6 ml sterile PBS in the nebulizer] aerosol for
30 min per day on odd days from d 13 to d 25, and chal-
lenged with 10 mg/ml OVA for 30 min per day on even
days from d 14 to d 26.
25 mg/ml inhaled test group (sensitized/25 mg/ml ketamine-
exposed/OVA-challenged rats, n = 8)
Sensitized rats were exposed to 25 mg/ml ketamine (100
mg/2 ml Ketamine Hydrochloride Injection diluted to 25
mg/ml with 2 ml sterile PBS in the nebulizer) aerosol for
30 min per day on odd days from d 13 to d 25, and chal-
lenged with 10 mg/ml OVA for 30 min per day on even
days from d 14 to d 26.
50 mg/ml inhaled test group (sensitized/50 mg/ml ketamine-
exposed/OVA-challenged rats, n = 8)
Sensitized rats were exposed to 50 mg/ml ketamine (100
mg/2 ml Ketamine Hydrochloride Injection in the neb-
ulizer) aerosol for 30 min per day on odd days from d 13
to d 25, and challenged with 10 mg/ml OVA for 30 min
per day on even days from d 14 to d 26.
50 µg/kg injected comparison group (sensitized/50 µg/kg ketamine 
i.p.-injected/OVA-challenged rats, n = 6)
Rats were sensitized, and then 14 days later given i.p.
injections of 50 µg/kg ketamine (100 mg/2 ml Ketamine
Hydrochloride Injection). The rats were challenged with
10 mg/ml OVA for 30 min at 60 min post-i.p. injection,
and on even days from d 14 to d 26.
100 µg/kg injected comparison group (sensitized/100 µg/kg 
ketamine i.p.-injected/OVA-challenged rats, n = 6)
Rats were sensitized, and then 14 days later given i.p.
injections of 100 µg/kg ketamine (100 mg/2 ml Ketamine
Hydrochloride Injection). The rats were challenged with
10 mg/ml OVA for 30 min at 60 min post-challenged
injection, and on even days from d 14 to d 26.
The effects of nebulized ketamine at different concentra-
tions on the normal lung structure and the plasma levels
were evaluated by exposure non-sensitized rats to aerosol
of ketamine at 12.5 mg/ml or 25 mg/ml or 50 mg/ml
respectively for 30 min once every 2 d from d 13 to d 26.
Aerosol exposure was accomplished by placing 3–4 rats
from the same group in a plexiglass chamber (30 × 30 ×
30 cm3) connected to an ultrasonic nebulizer (S-888E,
Sino-Foreign, Dolphin Nanjing Electronics Co., China),
which generated an aerosol mist (particle size approxi-
mately 2–4 µm) with a drive flow rate of 5 liters/min
according to specifications of the manufacturer.
Assessment of airway responsiveness in vivo
Airway reactivity to Ach was assessed in vivo 16–18 hr
after the last OVA challenge, as previously described [19].
Rats were anesthetized with pentobarbital sodium (100
mg/kg i.p.), a tracheal cannula was inserted via tracheot-
omy for mechanical ventilation, and a small catheter
(22G) was inserted into the external jugular vein for Ach
administration. The rat was then placed in a sealed whole
body plethysmograph and connected to a rodent ventila-
tor (ML-V2, Peking SYNOL High-Tech Co., Beijing,
China), and ambient air was administered with a tidal
volume of 8 ml/kg and a frequency of 80 strokes per
minute. Transducers (ML-AMP II, Peking SYNOL High-
Tech Co., Beijing, China) connected to the ventilatory cir-
cuit provided voltage signals of pressure and flow, which
were amplified and transmitted to the analog/digital (A/
D) card (National Instruments Texas, USA) of a micro-
computer running the AniRes2003 software (Peking
Biolab Tech Co., Beijing, China), which was used to calcu-
late the inspiratory resistance (Ri), expiratory resistance
(Re) and dynamic compliance (Cldyn) of the respiratory
system from the digitized pressure and flow signals. After
stabilization of respiratory parameters (10–15 min), the
rat was given Ach (dissolved in 0.9% NaCl) intravenously
at an initial dose of 12.5 µg/kg, with the dose increasing
two-fold each injection up to 200 µg/kg, to obtain a
response curve of lung resistance (RL) increase over base-
line. The typical injection volume was 100 µl, delivered
over 3–4 s, and injections were administered at intervals
of ~5–6 minutes, based on the criterion that the RL must
return to the pre-Ach level before initiation of the next Ach
administration. The response was measured as the peak
increase above the baseline immediately after Ach admin-
istration.
Bronchoalveolar lavage
After assessment of airway reactivity, the rats were bled
and sacrificed under overdose anesthetic. Lungs were lav-
aged via the tracheal cannula with three times, once with
1 ml and twice with 1.5 ml (using sterile PBS in both
cases). Lavage fluid was recovered by gentle manual aspi-
ration with a syringe. The retrieved volume, which aver-
aged 75–80% of the instilled PBS, was immediately
centrifuged (500 g × 10 min at 4°C) and the supernatantJournal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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was stored at -20°C until it was used for measurement of
IL-4 and IL-13 levels. The pellet was kept on ice, washed
twice with PBS and resuspended in 1 ml of PBS. Total
numbers of leukocytes in the bronchoalveolar lavage fluid
(BALF) were determined with a Coulter counter(Coulter
Electronics Ltd., Harpeneden, UK). A differential cell
count was performed on Cytospin (Thermo Shandon,
Pittsburgh, PA) by Wright – Giemsa staining.
Histological examination of lung sections
Following sacrifice, the right main bronchus of each rat
was immediately separated and ligated, and the right
lungs were removed and rinsed with diethylpyrocar-
bonate (DEPC)-treated water. The lung tissues were
divided into several portions, frozen in liquid nitrogen,
and stored at -70°C until use for RT-PCR and Western blot
analysis. A cannula was inserted into the pulmonary
artery via the right ventricle, and the left lung of each rat
was perfused in situ, with fluids draining to the left atrium
outflow, above the level of the atrium. Initially, the lungs
were perfused with 0.9% NaCl (with a dilution 1:10000
of heparin) in an open, nonrecirculating mode at a rate of
8 ml/min for 10 min, for removal of residual blood. Next,
the lungs were fixed by perfusion at 4 ml/min with 4%
paraformaldehyde in 0.1 M PBS for 50 min. After per-
fusion, lung tissue samples were taken from peripheral
areas containing alveoli and microvessels, from central
lung areas containing mainstem bronchi, and from mid-
lung areas containing a mix of peripheral tissue and small
airways. These samples were stored in 4% paraformalde-
hyde, embedded in paraffin, sliced into 5 µm-thick sec-
tions and stained with hematoxylin-eosin. The
histological sections were examined by semiautomatic
morphometry using the LEICA Qwin 2.6 Image Process-
ing and Analysis System (Leica Cambridge, Cambridge,
England) coupled to a LEICA Qwin DC 300F digital cam-
era. The lung sections were assigned a score of 0–4 (0, no
inflammation; 1, mild inflammation; 2, moderate inflam-
mation; 3, severe inflammation; 4, extreme inflamma-
tion), as previously described by Stenton et al. [20].
Inflammation was scored by a pathologist who was blind
to the various treatments, and the inflammatory scores
were based on the presence of congestion, hemorrhage,
edema (alveolar and interstitial), and/or inflammation
(airway lumen, airway wall, alveolar, interstitial, and
perivascular).
Assay of IL-4/IL-13 concentration in BALF
The supernatant obtained from the BALF was assayed for
interleukin-4 (IL-4) and interleukin-13 (IL-13) concentra-
tion within one month of processing, using the enzyme-
linked immunosorbent assay (ELISA)-based Quantikine
M kits specific for rat IL-4 and IL-13 (R&D Systems, Min-
neapolis, USA), according to the manufacturer's instruc-
tions. Each kit had a sensitivity of < 5 pg/ml. The
polynomial equation (y = a + bc + cx2) was used to create
a curve for standards containing known concentrations of
each cytokine, and the IL-4 and IL-13 concentrations in
the BALF samples were calculated from the line equation
and the sample dilution factor.
RT-PCR analysis of Nitric Oxide Synthase (NOS) mRNA 
expression
Total RNA was extracted from lung tissues using the Trizol
Reagent (Invitrogen, Carlsbad, CA), according to the man-
ufacturer's protocol. Reverse transcription (RT) was per-
formed with oligo(dT) using Superscript II RNA-reverse
transcriptase (Invitrogen, Carlsbad, CA). First-strand
cDNA synthesis was performed at 42°C for 1 h, the RNA-
cDNA hybrids were denatured at 90°C for 10 min, and
the RT products were stored at -20°C until use. PCR was
performed using a Hybaid PCR Express thermal cycler
(Peltier Thermal Cycler-200; MJ Research Inc., Massachus-
sets, USA).
Primer sequences were as follows: iNOS, 5'-
TTGGAGCGAGTTGTGGATTG-3' (sense) and 5'-GTGAG-
GGCTTGCCTGAGTGA-3' (antisense); eNOS, 5'-AGAC-
CGATTACACGACATTGAG-3' (sense) and 5'-
GACATCACCGCAGACAAACA-3' (antisense); nNOS, 5'-
AGAGGAGGACGCTGGTGTA-3' (sense) and 5'-GGCG-
GTTGGTCACTTCATA-3' (antisense); β-actin, 5'-ATGGT-
GGGTATGGGTCAGAAGG-3' (sense) and 5'-
CATGGCAGAAGAAAGACAATTA-3' (antisense).
The predicted sizes for the PCR products were 104 bp for
nNOS, 125 bp for iNOS, 274 bp for eNOS, and 315 bp for
β-actin. The PCR reactions consisted of 0.3 µL of each
primer, 2 µL of dNTP, 0.2 µL of Taq DNA polymerase and
4 µL of cDNA in a final volume of 20 µL. The PCR condi-
tions were as follows: 94°C for 5 min, followed by 32
cycles of denaturation at 94°C for 45s, annealing at 63°C
(iNOS), 61°C (eNOS) or 59°C (nNOS) for 45s, and
extension at 72°C for 45s, followed by a final extension at
72° for 10 min. β-Actin, which was used as an internal
control, was amplified under the following conditions:
94°C for 3 min, followed by 28 cycles of 94°C for 30s,
58°C for 30s, 72°C for 30s and 72° for 10 min. The reac-
tion products were resolved by agarose gel electrophore-
sis, stained with ethidium bromide (10 mg/ml),
visualized under UV transillumination and photographed
with a Canon TV Zoom Lens (Canon, Tokyo, Japan) in an
Epi Chemi II Darkroom (UVP Laboratory Products,
Upland, CA). Relative mRNA expression was estimated by
comparison to the relative intensities of known DNA
standards and β-actin.
Measurement of iNOS protein levels by Western Blot
For Western Blotting, 180–220 mg of pulmonary tissue
was placed in 1 ml of lysis buffer (50 mM Tris-HCl, pHJournal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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7.5, 0.3 M NaCl, 1% NP-40, 0.1% SDS, 1 mM EDTA, 10
µg/ml aprotinin, 100 µg/ml leupeptin, 1 mmol/L PMSF)
and homogenized on ice using an homogenizer (IKA-
ULTRA-TURRAX T25, IKA-WERKE GMBH & CO., KG,
Germany) for four bursts of 10–15 s at 20 s intervals. The
homogenate was centrifuged at 14,000 g for 10 min at
4°C (5810R, Eppendorf AG 22331; Eppendorf, Hamburg,
Germany), the supernatant was collected, and the protein
concentration was determined by the Bradford assay.
Aliquots containing ~30 µg of protein were resolved in a
40 mA system(Bio-Rad, Hercules, CA, USA) consisting of
an 8% polyacrylamide resolving gel and a 5% polyacryla-
mide stacking gel. The resolved proteins were electropho-
retically transferred to PVDF membranes at 100 V for 1 hr.
The membranes were washed in PBS buffer (pH 7.4) con-
taining 0.1% (v/v) Tween-20 (PBST), blocked with 5%
BSA/PBST (m/v) for 1 hour at 37°C, and then incubated
overnight at 4°C with monoclonal anti-iNOS antibodies
(N9657; Sigma-aldrich, Inc. Missouri, USA) diluted
1:1000 in 5% BSA/PBST. The membranes were then
washed three times (5 min each) with PBST and incubated
for 1 hour with horseradish peroxidase-labeled goat anti-
mouse IgG diluted 1:2000 in 5% BSA/PBST. Immunoreac-
tive bands were detected by chemiluminescence (Photo-
tope®-HRP Western Blot Detection System; Cell Signaling,
UK), and the results were visualized by autoradiography,
photographed with a Canon TV Zoom Lens in an Epi
Chemi II Darkroom, and analyzed for the relative inten-
sity of the iNOS signal versus that of β-actin, using the
Gel-Pro Analyzer software (Media Cybernetics Inc., Geor-
gia, USA).
Assay of Nitric Oxide (NO) production
Nitric oxide production was determined by colorimetric
measurement of nitrite, which is the stable end product of
nitric oxide metabolism. Briefly, pulmonary tissues were
homogenized in buffer (1/10, w/v) containing 0.05 mol/
L Tris-HCl, pH 7.5, 0.025 mol/L sucrose, and 0.1 mmol/L
EDTA. Then this lysate was centrifuged at 1500 g for 10
min. The supernatant or a sodium nitrite standard (100
µL each) was reacted with an equal volume of Griess rea-
gent (1% sulphanilamide, 0.1% N-(1-Napthyl) Ethylene-
diamine dihydrochloride, 2.5% phosphoric acid; Griess
Reagent Kit, JianCheng, Jiangsu, China) in duplicate wells
of a microtiter plate for 10 min at room temperature.
Chromophore absorbance at 550 nm was determined
using a microplate reader (Beckman Coulter, Germany).
Equation is established by running known concentrations
of sodium nitrite and then plotting absorbance vs. con-
centration. The concentration of nitrite in the samples was
calculated by comparison to the standard curve of sodium
nitrite.
Determination of plasma ketamine concentration
After the last administration of nebulized ketamine by
inhalation, blood samples of ~0.5 ml were collected at 0,
5, 10, 20, 40 and 60 min post-dosing from rats in 12.5
mg/ml, 25 mg/ml, and 50 mg/ml ketamine inhalation
control groups respectively. The rats were then killed by
overdose anesthetic, and processed for histological exam-
ination. Another blood sample was collected from a naive
Brown-Norway rat as blank plasma for ketamine stand-
ard. The blood samples were centrifuged at 1500 rpm for
10 min, and the plasma was stored at -20°C until analysis.
Ketamine(white crystalline powder, pure degree 99. 8 %,
05051112, Jiangsu Hengrui Medicine Co., China) was
dissolved in methanol to prepare standard stock solutions
at concentrations of 5, 0.5 and 0.1 g/L and phenacetin
(internal calibrator) was dissolved in methanol at 10 mg/
L to make standard stock solution. These solutions were
stored at -80°C. Prior to experiments, ketamine standard
stock solutions were used to make standard working solu-
tions of the appropriate dilutions with blank plasma at
serials of concentrations of 250, 500, 2000, 10000 µg/L.
Ketamine levels in the plasma samples were measured by
high performance liquid chromatography (HPLC) with
fluorescent detection [21] using the system of Prominence
Series Modular HPLC (Shimadzu Scientific Instruments,
Kyoto, Japan). Separation was achieved using a Diarnosil
C18 column (5 µm, 4.6 mm × 250 mm). The mobile phase
consisted of a 65:35 (v/v) mix of acetonitrile and phos-
phate buffer (an equal mixture of 0.025 mol/L K2HPO4
and 0.003 mol/L KH2PO4) adjusted to pH 7.2. The flow
rate of the mobile phase was 1.0 ml/min, the detection
wavelength was 220 nm, and the system was used at
ambient temperature (~30°C). For plasma preparation,
~0.2 ml sample plasma or 0.2 ml of ketamine standard
series was mixed with 20 µL of internal calibrator, alkali-
nized with 20 µL of 0.2 mol/L NaOH, and vortexed for 10
min at 60 rpm, then extracted with 2 ml of a mixture con-
taining N-hexane, lsopropylalcohol and dichloromethane
(64:3:33 by vol). The mixture was centrifuged at 3500
rpm for 10 min at 15°C, and the organic layer was trans-
ferred to a conical glass tube and evaporated to dryness
under a gentle nitrogen stream. Finally, the dried residue
was reconstituted in 100 µL of mobile phase, and an aliq-
uot of 20 µL was injected into the C18 column.
Calibration curves containing an internal correction
standard were fitted by plotting the peak height ratio of
the ketamine to the phenacetin vs. the known concentra-
tion of ketamine standard solutions. The concentration of
ketamine in the samples was calculated on calibration
curves of ketamine standard.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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Data analysis
All statistical analyses were performed using the SPSS soft-
ware (version 13.0 for Windows, Northwestern University
Information Technology, Evanston). Comparisons were
carried out using ANOVA and Dunnett's test. The log
transformation linear regression U-test was used to exam-
ine pair-wise differences in concentration under same %
increase of Re, and the post-hoc Bonferroni method was
used to adjust the resulting P-values. The presented data
are expressed as the mean ± the standard error of the mean
(SEM). Differences were considered statistically signifi-
cant at P < 0.05.
Results
Effects of ketamine on ovalbumin-induced airway 
hyperresponsiveness
In response to increasing doses of intravenously adminis-
tered Ach, all experimental rats showed dose-dependent
increases in Re. There was no statistically significant differ-
ence in baseline value of Re among all experimental
groups (data not shown). The airway responsiveness to
Ach increased in OVA control group when compared with
that of PBS-exposed animals. This is illustrated by a left-
ward shift of the dose-response curve (Figure 1A). In addi-
tion, the provocation doses required to increase Re by
100, 200 and 400 % in OVA control rats were significantly
lower than those of PBS control rats (14.65 ± 1.19 µg/kg
vs. 32.28 ± 1.43 µg/kg, P < 0.001; 15.17 ± 1.19 µg/kg vs.
38.91 ± 1.39 µg/kg, P < 0.001 and 16.28 ± 1.18 µg/kg vs.
56.53 ± 1.38 µg/kg, P < 0.001, respectively; Figures 1B, C,
D). Treatment with ketamine either via inhalation or
injection prior to OVA challenge in OVA-sensitized rats
prevented this increase in airway reactivity, reflected by
right-ward shifts of the dose-response curves and signifi-
cant increases in the provocation doses, when compared
with OVA control rats. In groups receiving 12.5, 25 and 50
mg/ml ketamine by inhalation and 50 and 100 µg/kg ket-
amine by i.p. injection, the doses required to increase the
Re by 100% (PC100) were 31.09 ± 1.51 µg/kg (P < 0.001),
20.44 ± 1.28 µg/kg (P = 0.019), 25.57 ± 1.38 µg/kg (P <
0.001), 24.02 ± 1.32 µg/kg (P < 0.001) and 20.39 ± 1.29
µg/kg (P = 0.022) respectively. Similarly, the values of
PC200 and PC400 in all ketamine pretreatment groups
were significantly higher than those of OVA control rats(P
< 0.001).
Effects of ketamine on ovalbumin-induced airway 
inflammation
Inflammatory cell infiltrate in BALF
The majority of cells identified in the BALF of rats were
macrophages (approximate 76–86 %), with smaller pop-
ulations of eosinophils, neutrophils, and lymphocytes
observed. Remarkably, the total cellularity of BALF recov-
ered from OVA control rats showed significantly higher
than from PBS-exposed rats (5.97 ± 0.72 × 106 vs. 2.51 ±
0.49 × 106, P < 0.001; Figure 2A). Differential cell count-
ing revealed a significantly higher percentage of eosi-
nophils and lymphocytes and a decrease in the percentage
of macrophages in OVA control animals compared with
these parameters in PBS control animals (P < 0.001, P =
0.002 and P = 0.034, respectively; Figure 2B). Treatment
with 12.5, 25 and 50 mg/ml nebulized ketamine or 50
and 100 µg/kg i.p.-injected ketamine inhibited OVA-
induced increases in total BALF cell number by 46, 53, 41,
48 and 41% respectively, compared with OVA control ani-
mals (Figure 2A). The proportions of eosinophils in BALF
from 12.5, 25 and 50 mg/ml inhaled ketamine-treated
rats were 5.16 ± 1.07, 4.54 ± 0.78 and 5.31 ± 0.91%,
respectively, and those in 50 and 100 µg/kg i.p.-injected
ketamine-treated rats were 4.92 ± 0.66 and 5.02 ± 0.91%,
compared with 9.56 ± 0.99% in OVA control animals (P
= 0.002, P < 0.001, P = 0.004, P = 0.003 and P = 0.004
respectively). Moreover, ketamine pretreatment prior to
OVA challenge rescued the percentages of lymphocytes in
the BALF of OVA-sensitized rats to 3.15 ± 0.62, 3.25 ±
0.28, 3.22 ± 0.73, 3.08 ± 0.91 and 3.36 ± 1.10 %, com-
pared with 6.08 ± 0.56 % in OVA-sensitized and -chal-
lenged rats (P = 0.01, P = 0.014, P = 0.013, P = 0.016, P =
0.035 respectively; Figure 2B).
Lung histology
In PBS-treated rats, the small bronchi, bronchioles and
lung alveoli were structurally normal, the mucosal epithe-
lia were intact, and no inflammation was present (Figure
3A). Conversely, the airways of OVA control rats showed
marked inflammatory changes, including desquamation
of the bronchial epithelia, the presence of secretions and
damaged cells inside the lumens of bronchi and alveoli,
and patchy inflammatory infiltration in the bronchial
submucosa, perivascular areas and the surrounding alveo-
lar septa. These infiltrates consisted primarily of mononu-
clear cells and some eosinophils. In addition, we observed
that OVA exposure induced goblet cell hyperplasia, hem-
orrhage, congestion, and alveolar and interstitial edema
(Figures 3B1, B2). Notably, ketamine-treated rats showed
less infiltration of inflammatory cells into peribronchial
and perialveolar areas, decreased interstitial edema, and
fewer epithelial lesions in the bronchi and bronchioles,
although the goblet cell hyperplasia and congestion trig-
gered by OVA exposure did not appear to be affected by
ketamine treatment (Figures 3C–G).
The mean inflammatory score significantly increased
from 1.43 ± 0.37 in PBS-exposed rats to 2.88 ± 0.23 in sen-
sitized rats challenged with OVA (P = 0.003). When com-
pared with OVA control animals, inflammatory scores
were significantly decreased at the level of 12.5 or 25 mg/
ml nebulized ketamine or 50 µg/kg i.p.-injected ketamine
1.57 ± 0.2 (P = 0.009), 1.71 ± 0.29(P = 0.023), 1.7 ±
0.44(P = 0.043) respectively, while the dose of 50 mg/mlJournal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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nebulized ketamine or 100 µg/kg i.p.-injected ketamine
did not show statistical signifiance(Figure 4). There was
no statistically significant difference in pulmonary inflam-
matory scores and the changes of lung structure among
PBS-treated controls and non-sensitized rats receiving
inhaled ketamine at concentrations of 12.5, 25 or 50 mg/
ml (data not shown).
Levels of IL-4 and IL-13 in BALF
BALF from PBS control rats contained 82.81 ± 7.87 pg/ml
of IL-4, whereas this level was 2- to 3-fold higher in OVA
control animals with a mean concentration of 215.33 ±
20.75 pg/ml (P = 0.004). OVA-sensitized and -challenged
rats treated with 12.5 or 25 mg/ml nebulized ketamine or
50  µg/kg i.p.-injected ketamine showed significant
decreases in IL-4 protein levels compared to OVA control
animals (121.30 ± 11.18 pg/ml, P = 0.036; 119.33 ± 14.60
pg/ml, P = 0.041; 108.60 ± 9.34, P = 0.016, respectively).
There was no statistical difference in IL-4 levels among rats
receiving 50 mg/ml inhaled ketamine or 100 µg/kg i.p.-
injected ketamine and OVA control rats (Figure 5A). In
terms of IL-13, OVA-sensitized/PBS-exposed/OVA-chal-
Effects of ketamine on ovalbumin-induced airway hyperresponsiveness in vivo Figure 1
Effects of ketamine on ovalbumin-induced airway hyperresponsiveness in vivo. Airway reactivity to intravenous ace-
tylcholine (Ach) was measured 16–18 hr after the last challenge, and is given as the increase in expiratory resistance (Re). (A) 
Responses were calculated as log percentages of the maximum Re increase above baseline following administration of different 
concentrations of Ach. (B, C, D) PC100, PC200 and PC400 represent the provocation concentration required to increase Re 
by 100, 200 and 400%, respectively. The log transformation linear regression U-test was used to examine pair-wise differences 
in concentration under the same % increase of Re above baseline, with the post-hoc Bonferroni method used to adjust the P-
values. The data presented are given as the mean ± SEM (n = 6–8). # P < 0.05 vs. PBS control, * P < 0.05 vs. OVA control. PBS, 
negative control; OVA, positive control; 12.5 mg/ml, OVA-sensitized/12.5 mg/ml nebulized ketamine-exposed/OVA-challenged; 
25 mg/ml, OVA-sensitized/25 mg/ml nebulized ketamine-exposed/OVA-challenged; 50 mg/ml, OVA-sensitized/50 mg/ml neb-
ulized ketamine-exposed/OVA-challenged; 50 µg/kg, OVA-sensitized/50 µg/kg ketamine-injected i.p./OVA-challenged; 100 µg/
kg, OVA-sensitized/100 µg/kg ketamine-injected i.p./OVA-challenged.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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lenged animals had significantly higher IL-13 levels
(140.73 ± 16.47 pg/ml) compared to PBS-challenged rats
(48.40 ± 5.57 pg/ml, P = 0.009). Treatment with inhaled
or injected ketamine appeared to decrease the IL-13 levels
in BALF, but these differences did not reach the level of
statistical significance(Figure 5B).
NOS mRNA expression in pulmonary tissues
RT-PCR was used to examine the expression of nNOS,
iNOS and eNOS in pulmonary tissues from rats in all
treatment groups. Expression of iNOS and eNOS was
detected in the studied samples, but nNOS was not (Fig-
ure 6A). The internal control housekeeping gene, β-actin,
was used to calculate relative mRNA expression levels. We
found that iNOS mRNA expression was significantly
higher in OVA controls versus PBS controls (1.00 ± 0.07
vs. 0.48 ± 0.07, P < 0.001). Ketamine treatment signifi-
cantly decreased iNOS mRNA expression in OVA-sensi-
tized and -challenged rats receiving 12.5 (0.65 ± 0.07, P =
0.01), 25 (0.58 ± 0.09, P = 0.002) or 50 (0.56 ± 0.100, P
= 0.001) mg/ml inhaled ketamine, or 50 µg/kg i.p.-
injected ketamine (0.66 ± 0.06, P = 0.028) respectively. In
contrast, there was no significant difference in eNOS
mRNA expression levels among the various experimental
groups (Figure 6B).
iNOS protein expression in pulmonary tissues
Western blot analysis was used to semiquantitatively
examine protein expression of iNOS (120 kDa) and β-
actin (46 kDa) (Figure 7A). The relative iNOS protein lev-
els (ratios of iNOS/β-actin) determined by densitometry
showed 4-fold higher levels in OVA control rats versus
Effects of ketamine treatment on changes in total and differential cell numbers in BALF from ovalbumin-sensitized and -chal- lenged rats Figure 2
Effects of ketamine treatment on changes in total and differential cell numbers in BALF from ovalbumin-sensi-
tized and -challenged rats. The total (A) and differential (B) cell numbers were counted in BALF from rats in the various 
treatment groups. Bars represent mean ± SEM (n = 6–8/group). # P < 0.05 vs. PBS control, * P < 0.05 vs. OVA control. The 
groups are as shown in Figure 1.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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PBS controls (0.54 ± 0.08 vs. 0.13 ± 0.03, P=0.012),
whereas the OVA-induced increases were significantly
lower in OVA-sensitized and -challenged rats receiving
12.5 mg/ml inhaled (0.20 ± 0.03, P = 0.036), 25 mg/ml
inhaled (0.18 ± 0.03, P = 0.027), or 50 µg/kg i.p.-injected
(0.21 ± 0.04, P = 0.045) ketamine (Figure 7B). However,
50 mg/ml inhaled or 100 µg/kg i.p.-injected ketamine did
not show statistical significance.
NO production in pulmonary tissues
NO production in pulmonary tissues was significantly
higher in OVA control rats compared to PBS-challenged
controls (0.39 ± 0.04 µmol/g protein vs. 0.13 ± 0.01
µmol/g protein, P = 0.005), but this OVA-triggered NO
production was significantly decreased by treatment with
12.5 or 25 mg/ml inhaled ketamine (0.19 ± 0.03 µmol/g
protein, P = 0.032; 0.17 ± 0.03 µmol/g protein, P = 0.014,
respectively) or 50 µg/kg i.p.-injected ketamine (0.16 ±
0.04 µmol/g protein, P = 0.022) when compared with
OVA control rats. In contrast, no significant difference in
NO production was observed in OVA-sensitized and -
challenged rats treated with 50 mg/ml inhaled or 100 µg/
kg i.p.-injected ketamine versus OVA controls(Figure 8).
Plasma concentration-time curves of ketamine
Chromatogram of a blank plasma supplemented with ket-
amine and phenacetin at a ketamine concentration of 500
µg/L is shown Figure 9A, and a plasma sample obtained 0
Effects of ketamine on histopathological changes seen in pulmonary sections from ovalbumin-sensitized and -challenged rats Figure 3
Effects of ketamine on histopathological changes seen in pulmonary sections from ovalbumin-sensitized and -
challenged rats. Representative paraffin-embedded, Hematoxylin and Eosin-stained lung sections were prepared from the left 
lungs of experimental rats, showing bronchioles, lung alveoli and surrounding vessel structures. The groups are as shown in Fig-
ure 1. (A) PBS; (B1-B2) OVA; (C) 12.5 mg/ml; (D) 25 mg/ml; (E) 50 mg/ml; (F) 50 µg/kg; (G) 100 µg/kg. VL, vascular lumen; AL, 
airway lumen. Arrows demonstrate marked perivascular edema (B1, G), places where inflammation has destroyed a portion of 
the airway epithelium (B2, F), and eosinophils (B1, C, E). Arrowheads indicate peribronchial inflammation (B1, C, D, E, F, G), 
hemorrhage (B2, E, F, G) and congestion (B2). Sections were evaluated under light microscopy. Original magnification was ×40, 
and the scal bars represent 20 µM.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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min after inhalation of 25 mg/ml ketamine is shown Fig-
ure 9B. Our results revealed that there was no detectable
interference due to interactions between ketamine or
phenacetin and endogenous materials in blood plasma.
The separation of the ketamine and phenacetin was
achieved in about 10 min. The retention times of keta-
mine and phenacetin in our system were determined to be
about 5.87 and 2.58 min. The minimum detectable
amount of ketamine at a signal-to-noise ratio of 4 was
found to be 5 µg/L.
Calibration curves were found to be linear in the range of
250–10,000  µg/L ketamine (R2  = 0.9984, data not
shown). Plasma ketamine concentration vs. time profiles
showed that the plasma concentration decreased sharply
at the initial time points and then decreased more slowly
after 20 min post-dosing. In rats receiving 12.5, 25 and 50
mg/ml nebulized ketamine, the plasma peak levels of ket-
amine were actually tested 890.33 ± 65.30, 1313.50 ±
151.65 and 2806 ± 596.14 µg/L respectively, these were
occurred at 0 min. Plasma drug clearance was found to be
an exponential function, and the plasma ketamine con-
centrations over time could be fitted to the following
equations: Cfitted  = 792.68*0.97time(F = 106.34, P =
0.0003, R2 = 0.98); Cfitted = 1133.82*0.97time(F = 65.32, P
= 0.0009, R2 = 0.97); Cfitted = 2288.63*0.96time(F = 28.08,
P = 0.0044, R2 = 0.93). (Figure 9C).
Discussion
In this study, we investigated possible therapeutic effects
of inhaled ketamine solution on allergic asthma, using an
OVA-induced asthma model in Brown-Norway rats. We
found that ketamine treatment yielded anti-inflammatory
effects, as evidenced by lung histological examination,
total and differential cell counts in BALF, Th2 cytokine
levels in BALF, and iNOS expression and NO content in
pulmonary tissues. Furthermore, the results of Ach-elic-
ited airway response tests indicated that ketamine treat-
ment by both inhaled and injected routes could attenuate
OVA-induced AHR. Finally, inhalation of nebulized keta-
mine did not induce toxicological changes in lung tissues
and was associated with a much lower plasma concentra-
tion, suggesting that nebulized ketamine may prove to be
a safe and effective aerosol therapy for allergic asthma.
Intraperitoneal injection of ketamine was set as parallel
comparison in this experiments, the aim was to observe
whether the effect of nebulized ketamine on OVA-
induced inflammatatory changes and AHR was as effective
as that of ketamine administration by systemic route. The
doses of ketamine tested by intraperitoneal injection were
50 and 100 µg/kg, with the latter corresponding to the
anesthetic dose for rats. In a previous study by Rock et al.
[22], four of six guinea pigs receiving 10 mg/ml aero-
solized ketamine had a lower peak airway resistance com-
pared with PBS controls, though this difference did not
reach statistical significance. The authors speculated that
this lack of significance might have been due to the small
sample size. However, aerosol concentration may also be
an important factor in evaluating the efficacy of an inha-
lotherapy, as the therapeutic response to an inhaled drug
is a function of the drug dose that is actually deposited at
the action site within the lung [3]. Therefore, based on the
previous findings with 10 mg/ml inhaled ketamine, we
herein examined the effect of 12.5, 25 and 50 mg/ml
inhaled ketamine. Our results showed that inhalation of
ketamine at 12.5 or 25 mg/ml concentration is as effective
as systemic administration of ketamine at dose of 50 µg/
kg for the treatment of experimental asthma in vivo.
The Brown-Norway rat model of allergen-induced
asthma, which has been used extensively to evaluate the
pathophysiological mechanisms of this disease, reflects
many features of human allergic asthma, including both
early and late phase reactions, increased antigen-specific
IgE levels following active immunization [23], increased
bronchial responsiveness to multiple stimuli following
allergen challenge [24], and airway inflammation [17].
OVA sensitization alone has no effect on airway respon-
siveness and does not elicit measurable airway inflamma-
tion in this model [17,25]; in contrast a single OVA
challenge induces transient AHR, and multiple OVA aero-
sol challenges trigger persistent AHR [17]. In the present
Effects of ketamine on inflammatory scores in lung tissues  from ovalbumin-sensitized and -challenged rats Figure 4
Effects of ketamine on inflammatory scores in lung 
tissues from ovalbumin-sensitized and -challenged 
rats. Lungs were sampled after measurement of airway reac-
tivity and scored under the light microscope at a magnifica-
tion of ×40. Bars represent mean ± SEM (n = 6–8/group). # P 
< 0.05 vs. PBS control, * P < 0.05 vs. OVA control. The 
groups are as shown in Figure 1.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
Page 11 of 16
(page number not for citation purposes)
study, sensitized Brown-Norway rats were subjected to
repeated intermittent (thrice weekly) exposure to aero-
solized OVA for two weeks. This triggered the result of
increased AHR to Ach and an obvious airway inflamma-
tion observed 24 h after the last OVA challenge, which was
in accordance with the report of Palmans et al. [26], con-
firming the co-existence of high airway reactivity and
allergic inflammation in sensitized Brown-Norway rats
after 2 weeks of OVA exposure.
Measurement of airway responsiveness to bronchocon-
strictor stimuli continues to be advocated as a useful diag-
nostic test for evaluating possible asthmatics [27]. Airway
responsiveness may be defined as the normal tendency for
airways to constrict under the influence of various stimuli.
When direct-acting bronchoconstrictors(Ach, metha-
choline, and carbachol) are used, hyperresponsiveness
can be defined as increases in both the ease and magni-
tude of bronchoconstriction [27]. In our study, the left-
ward shift of dose-response curve corresponding to Ach-
induced airway reactivity in OVA control group showed a
higher magnitude of the maximal dose-response plateau
under same dose of Ach, indicating an increased magni-
tude of bronchoconstriction. In addition, the lower values
of PC100, PC200, PC400 indicating an increase in the
ease of bronchoconstriction. Our experimental results
demonstrated that OVA induced AHR in experimental
rats, whereas this was attenuated by administration of
inhaled or injected ketamine. Ketamine is a potent bron-
chodilator that inhibits airway smooth muscle contrac-
tions by actions occurring within both the smooth muscle
cell and the vagal intramural ganglia [28]. The direct bron-
chorelaxing effects are likely to be achieved with the usual
clinical doses in airway rings [29].
Effects of ketamine on Interleukin-4 and Interleukin-13 protein levels in BALF from ovalbumin-sensitized and -challenged rats Figure 5
Effects of ketamine on Interleukin-4 and Interleukin-13 protein levels in BALF from ovalbumin-sensitized and -
challenged rats. IL-4 (A) and IL-13 (B) protein levels in BALF were measured by ELISA. Bars represent mean ± SEM (n = 6–
8/group). # P < 0.05 vs. PBS control, * P < 0.05 vs. OVA control. The groups are as shown in Figure 1.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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The presence of airways hyperresponsiveness and eosi-
nophilia as a late reaction 24 h after antigen challenge of
sensitized animals is well established in the literature
[30,31]. Eosinophils are a major source of inflammatory
mediators that can cause tissue damage and airway hyper-
responsiveness in allergic asthma [32]. One hallmark of
allergic asthma, namely inflammatory cell infiltration
into the bronchoalveolar space, was used to evaluate the
effect of different ketamine treatment regimens. Both
inhalation of ketamine at concentrations of 12.5 mg/ml,
25 mg/ml, 50 mg/ml and systemic administration of ket-
amine at doses of 50 µg/kg and 100 µg/kg were sufficient
to suppress allergen-induced inflammatory cell infiltra-
tion into the parenchyma and alveoli from the observa-
tion of lower total and eosinophil counts in BALF.
Accumulating data seem to indicate that unbalanced and
aberrant Th2 inflammation is the main cause of allergic
asthma. The activation of T lymphocytes and the produc-
tion of cytokine mediators, leading to subsequent recruit-
ment of effector eosinophils, may be a common pathway
in the pathogenesis of asthma [33]. There is little contro-
versy about the requirements for IL-4 in the induction of
airway inflammation and AHR [34], while IL-13 direct
causes AHR and mucus overproduction in asthma
[35,36]. Both promote interaction of vascular cell adhe-
Effects of ketamine on NOS mRNA expression in pulmonary tissues from ovalbumin-sensitized and -challenged rats Figure 6
Effects of ketamine on NOS mRNA expression in pulmonary tissues from ovalbumin-sensitized and -chal-
lenged rats. (A) Expression of NOS mRNA in pulmonary tissues was detected by RT-PCR. Representative RT-PCR products 
for nNOS, iNOS, eNOS and β-actin (internal control) are shown. The groups are as shown in Figure 1. Lane 1, PBS; lane 2, 
OVA; lane 3, 12.5 mg/ml; lane 4, 25 mg/ml; lane 5, 50 mg/ml; lane 6, 50 µg/kg; lane 7, 100 µg/kg. (B) Semiquantitative densitom-
etry was used to analyze iNOS and eNOS mRNA expression levels, normalized to that of β-actin. Bars represent mean ± SEM 
expressed as the relative density of NOS versus that of β-actin (n = 6–8/group). # P < 0.05 vs. PBS control; * P < 0.05 vs. OVA 
control.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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sion molecule 1(VCAM-1) with the very late activation
antigen 4 (VLA-4) of eosinophil activation and recruit-
ment [37]. Previous studies in vivo and in vitro have con-
firmed that ketamine could reduce inflammatory cytokine
production/release and inhibit certain cytokine effects
[38-40]. The present study showed that ketamine treat-
ment decreased the percentage of lymphocyte in BALF. In
particular, administration of nebulized ketamine at 12.5
mg/ml and 50 mg/ml and injection of ketamine at dose of
50 µg/kg significantly down-regulate Th2 cytokine IL-4
secretion in BALF, which suggest that ketamine treatment
could alleviate IL-4-mediated responses, airway inflam-
mation and AHR.
Recent findings suggest that NO may be involved in the
pathophysiology of asthma, excessive production of NO
in asthma may be cytotoxic, and may also contribute to
the pathologic changes (e.g. airway edema, mucus pro-
duction, and inflammatory cellular infiltration) seen in
patients with asthma, particularly during asthma exacer-
bations [41,42]. The non-invasive measurement of NO in
exhaled air seems accurately to reflect inflammation in the
airways and may be of value in monitoring airway dis-
eases such as asthma. Although high NO output is poorly
correlated with the degree of bronchoconstriction, this
parameter correlates well with other inflammatory mark-
ers, including airway eosinophilia [43]. NO is synthesized
Effects of ketamine on iNOS protein expression in pulmonary tissues from ovalbumin-sensitized and -challenged rats Figure 7
Effects of ketamine on iNOS protein expression in pulmonary tissues from ovalbumin-sensitized and -chal-
lenged rats. Protein expression of iNOS in lung homogenates obtained from experimental rats was examined by Western 
blotting, with a representative example from each group shown. β-actin was detected as an internal control. The groups are as 
shown in Figure 1. (A) Lane 1, PBS; lane 2, OVA; lane 3, 12.5 mg/ml; lane 4, 25 mg/ml; lane 5, 50 mg/ml; lane 6, 50 µg/kg i.p,; lane 
7, 100 µg/kg. (B) Densitometric analysis of iNOS protein levels in lungs obtained from rats in each group. The bars represent 
the mean ± SEM, with laser densitometry used to standardize iNOS protein levels with respect to that of β-actin (ratio of 
iNOS/β-actin, n = 6–8/group). # P < 0.05 vs. PBS control; * P < 0.05 vs. OVA control.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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from the conversion of L-arginine to L-citrulline by nitric
oxide synthase (NOS), and at least three NOS isoforms,
differing in activity and tissue distribution, have been
identified. The two constitutively expressed isoforms,
endothelial NOS (eNOS) and neural NOS (nNOS), both
produce small (picomole) amounts of NO and mediate
physiological functions in healthy lungs. In contrast, the
third NOS isoform, inducible NOS (iNOS), is not
expressed in normal tissues and may be induced by
diverse cytokines or endotoxins, triggering extended pro-
duction of larger (nanomole) amounts of NO [44]. In the
present study, gene expression of eNOS and iNOS were
both detected, although nNOS was not detected in the
lung tissues from experimental rats. Significant differences
of iNOS gene expression observed between OVA control
rats and PBS-treated controls. This result was confirmed
by protein expression analysis of iNOS and NO content
analysis. Furthermore, ketamine pretreatment signifi-
cantly reduced the OVA-triggered up-regulation of iNOS
and NO levels, especially in nebulized ketamine at 12.5 or
25 mg/ml or injected ketamine at dose of 50 µg/kg. This is
consistent with the observation that ketamine prevented
the elevation of NO [45] and inhibited the activity and
protein expression of iNOS [12,46] in response to LPS in
vitro studies.
Our results indicated both 12.5 and 25 mg/ml inhaled
ketamine and 50 µg/kg i.p.-injected ketamine exerted
anti-inflammatory and anti-hyperresponsiveness roles in
an established experimental model of allergic asthma. The
peak plasma concentrations of ketamine in rats receiving
12.5, 25 and 50 mg/ml nebulized ketamine, as deter-
mined by HPLC, were far lower than 100 µM, which
meaning that these levels were within the range of clinical
relevance and without being cytotoxic to macrophages in
vitro[47].
In summary, inhaled ketamine appeared to effectively
block the inflammatory cascade response in an in vivo
model of allergic asthma. Nebulized ketamine at different
concentrations was found to suppress allergen-induced
AHR and elevation of inflammatory markers, but this
effect was not strictly dose-dependent within the scope of
12.5, 25, 50 mg/ml concentrations. Nebulized ketamine
at concentrations of 12.5 or 25 mg/ml significantly less-
ened OVA-induced airway inflammation and the induc-
tion of iNOS, IL-4 and NO in an experimental model of
asthma. This effect was ultimately accompanied by
reduced airway hyperresponsiveness, suggesting that neb-
ulized ketamine at 12.5 or 25 mg/ml might be beneficial
for the treatment of asthma.
Conclusion
Ketamine administration by local route appears to inhibit
the inflammatory cascade response in an experimental
asthma model in vivo. Inhalation of 12.5 or 25 mg/ml ket-
amine markedly suppressed OVA-provoked airway hyper-
reactivity (AHR), airway inflammation and airway
inflammatory cell infiltration into BALF, and significantly
decreased OVA-induced up-regulation of iNOS, IL-4 and
NO. These findings collectively indicate that nebulized
ketamine attenuates many of the central components of
inflammatory changes and AHR in an OVA-provoked
experimental asthma and may provide a new therapeutic
approach for the treatment of allergic asthma.
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Effects of ketamine on nitric oxide production in pulmonary  tissues from ovalbumin-sensitized and -challenged rats Figure 8
Effects of ketamine on nitric oxide production in pul-
monary tissues from ovalbumin-sensitized and -chal-
lenged rats. Nitric oxide production was determined by 
measurement of nitrite, and the results are expressed as 
µmol/g protein. Bars represent mean ± SEM (n = 6–8/group). 
# P < 0.05 vs. PBS control; * P < 0.05 vs. OVA control. The 
groups are as shown in Figure 1.Journal of Inflammation 2007, 4:10 http://www.journal-inflammation.com/content/4/1/10
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